Huenite, Cu4Mo3O12(OH)2, a new copper-molybdenum oxy-hydroxide mineral from the San Samuel mine, Carrera Pinto, Cachiyuyo de Llampos district, Copiapó Province, Atacama Region, Chile

Huenite, Cu4Mo3O12(OH)(2), is a new copper and molybdenum oxy-hydroxide mineral found in the San Samuel Mine, Carrera Pinto, Cachiyuyo de Llampos district, Copiapo Province, Atacama Region, Chile. This new species forms flattened orthorhombic prisms up to 60-70 mu m in size, weakly elongated along [001]. Huenite crystals were found on fractured surfaces of a quartz breccia, forming aggregates 1 mm in diameter in close association with lindgrenite, gypsum, dark grayish-brown tourmaline, and an unknown pale purple phase. The color is very dark reddish-brown, with a strong vitreous to adamantine luster. Its streak is pale reddish-brown to pinkish. The mineral is brittle with an irregular fracture and a Mohs hardness of 3.5-4 with a good cleavage on {010}. Its calculated density is 5.1 g/cm(3). The calculated refractive index is 2.18. Huenite is non-fluorescent under 254 nm (short wave) and 366 nm (long, wave) ultraviolet light. The empirical formula, calculated on the basis of 3 (Mo+S+Si) atoms per formula unit, is (Cu3.519Fe0.4032+)(Sigma 3.922 .)(Mo2.907S0.003Si0.003)(Sigma 3.000)O-12 center dot(OH)(2.229), with H2O content calculated for a total of 100 wt.%. Huenite is trigonal, with space group P3(1)/c and unit-cell parameters a = 7.653(5) angstrom, c = 9.411(6) angstrom, and V= 477.4(5) angstrom(3) for Z= 2. The eight strongest measured powder X-ray diffraction lines are: [d in angstrom, (I/I-0), (hkl)]: 2.974 (100) (112), 1.712 (59.8) (132), 3.810 (50.6) (110), 2.702 (41.2) (022), 2.497 (38.1) (120), 1.450 (37.2) (134), 6.786 (24.9) (010), and 5.374 (24.5) (011). The mineral, which has been approved by the CNMNC under number IMA 2015-122, is named in honor of Edgar Huen

Selection of wild ungulates by wolves Canis lupus

We investigated the patterns of wild ungulate selection by wolves in an 860 km 2 study area of the Northern Apennines (North Italy), in order to detect seasonal variation in wolf diet and changes of feeding habits in relation to the increased abundance of wild ungulates. From June 2007 to May 2008 we collected wolf scats and recorded the signs of presence of wild ungulate species along 25 transects, representative of the different habitat types within the study area. We analysed the scats to identify the main food items used by wolves in each season and we compared the proportions of biomass of wild ungulate species in the diet (use) to those calculated from the signs of presence (availability). We recorded significant seasonal changes in wolf feeding habits, but the main food items were wild ungulates, mainly wild boars, and medium-sized mammals. Livestock (sheep, goats, and calves) were used only in summer and early autumn, during the grazing period, in small quantities. Comparing the current diet of wolves to that recorded in the past in the same study area highlighted significant differences for wild ungulates and livestock, the former being more used nowadays and the latter less. Our study showed that, in the Northern Apennines, the feeding behaviour of wolves has evolved towards a greater use of wild prey, so reducing the impact on livestock and consequently wolf-human conflicts. Moreover, predation by wolves was directed towards the most abundant species of wild ungulates. © 2012 Copyright 2011 Dipartimento di Biologia Evoluzionistica dell'Università, Firenze, Italia

Development and Implementation of the AIDA International Registry for Patients With Still's Disease

Objective: Aim of this paper is to present the design, construction, and modalities of dissemination of the AutoInflammatory Disease Alliance (AIDA) International Registry for patients with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), which are the pediatric and adult forms of the same autoinflammatory disorder. Methods: This Registry is a clinical, physician-driven, population- and electronic-based instrument implemented for the retrospective and prospective collection of real-world data. The collection of data is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain evidence drawn from routine patients' management. The collection of standardized data is thought to bring knowledge about real-life clinical research and potentially communicate with other existing and future Registries dedicated to Still's disease. Moreover, it has been conceived to be flexible enough to easily change according to future scientific acquisitions. Results: Starting from June 30th to February 7th, 2022, 110 Centers from 23 Countries in 4 continents have been involved. Fifty-four of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 175 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 4449 fields organized into 14 instruments, including patient's demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. Conclusions: This international Registry for patients with Still's disease will allow a robust clinical research through collection of standardized data, international consultation, dissemination of knowledge, and implementation of observational studies based on wide cohorts of patients followed-up for very long periods. Solid evidence drawn from “real-life” data represents the ultimate goal of this Registry, which has been implemented to significantly improve the overall management of patients with Still's disease. NCT 05200715 available at https://clinicaltrials.gov/. Copyright © 2022 Vitale, Della Casa, Lopalco, Pereira, Ruscitti, Giacomelli, Ragab, La Torre, Bartoloni, Del Giudice, Lomater, Emmi, Govoni, Maggio, Maier, Makowska, Ogunjimi, Sfikakis, Sfriso, Gaggiano, Iannone, Dagostin, Di Cola, Navarini, Ahmed Mahmoud, Cardinale, Riccucci, Paroli, Marucco, Mattioli, Sota, Abbruzzese, Antonelli, Cipriani, Tufan, Fabiani, Ramadan, Cattalini, Kardas, Sebastiani, Giardini, Hernández-Rodríguez, Mastrorilli, Więsik-Szewczyk, Frassi, Caggiano, Telesca, Giordano, Guadalupi, Giani, Renieri, Colella, Cataldi, Gentile, Fabbiani, Al-Maghlouth, Frediani, Balistreri, Rigante and Cantarini

Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial

n/